Top Page
Imugene
(Sydney:IMU)
Imugene (IMU) vs. iShares MSCI Australia ETF (EWA)
Imugene Business Overview & Revenue Model
Imugene Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 10.81M | 11.78M | 12.97M | 7.23M | 4.13M |
| Gross Profit | 4.97M | 9.57M | 10.56M | 5.27M | 4.05M |
| EBITDA | -147.98M | -47.42M | -48.06M | -23.72M | -14.55M |
| Net Income | -149.68M | -37.91M | -37.87M | -18.45M | -10.51M |
Balance Sheet | |||||
| Total Assets | 151.40M | 197.06M | 147.61M | 71.81M | 65.20M |
| Cash, Cash Equivalents and Short-Term Investments | 94.54M | 153.15M | 99.89M | 29.49M | 30.11M |
| Total Debt | 1.55M | 553.47K | 673.43K | 271.03K | 69.34K |
| Total Liabilities | 33.14M | 7.44M | 8.90M | 6.79M | 5.40M |
| Stockholders Equity | 118.25M | 189.63M | 138.70M | 65.02M | 59.81M |
Cash Flow | |||||
| Free Cash Flow | -106.78M | -29.78M | -30.93M | -18.58M | -11.62M |
| Operating Cash Flow | -101.73M | -29.78M | -30.67M | -13.13M | -10.13M |
| Investing Cash Flow | -7.25M | 9.63K | -414.16K | -5.48M | -1.52M |
| Financing Cash Flow | 49.43M | 82.98M | 101.35M | 17.99M | 22.71M |
Imugene Technical Analysis
Imugene Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.38B | -0.04 | -62.85% | 2.34% | 15.18% | -2.87% | |
39 Underperform | $80.78M | ― | -99.05% | ― | ― | -33.99% | |
| ― | $85.46M | ― | -46.65% | ― | ― | ― | |
| ― | $84.00M | ― | -154.88% | ― | ― | ― | |
56 Neutral | AU$42.01M | ― | -36.95% | ― | ― | 11.11% | |
55 Neutral | AU$107.00M | ― | ― | ― | -33.01% | ||
40 Underperform | AU$118.95M | ― | -85.35% | ― | 315.11% | 51.16% |
Imugene Corporate Events
Imugene Limited has announced promising results from its Phase 1b clinical trial of azer-cel, an allogeneic CD19 CAR T therapy, in patients with relapsed diffuse large B-cell lymphoma (DLBCL). The trial has achieved a 79% overall response rate, with six complete responses and five partial responses, indicating significant potential for azer-cel in treating this aggressive form of blood cancer. The trial is expanding to include CAR T naïve patients with other types of lymphomas, and the safety profile of the treatment is manageable and well-tolerated. These developments could enhance Imugene’s position in the immuno-oncology field and provide new treatment options for patients with high unmet needs.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has issued 68,236,857 fully paid ordinary shares at $0.33 per share as part of a placement announced earlier. This issuance is part of their strategic efforts to fund ongoing research and development in their immunotherapy pipeline, positioning the company to advance its clinical and commercial milestones in the rapidly growing global cancer treatment market.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced the application for the quotation of 68,236,857 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective July 24, 2025. This move is part of previously announced transactions and reflects the company’s ongoing efforts to strengthen its financial position and support its strategic initiatives in the biotechnology sector.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited announced a change in the director’s interest, specifically regarding Leslie Chong’s holdings. The change involved the acquisition of 170,405 direct ordinary fully paid shares and the disposal of an equivalent number of performance rights under the Employee Share Option Plan. This adjustment reflects the company’s ongoing efforts to align executive interests with shareholder value, potentially impacting stakeholder perceptions and reinforcing Imugene’s commitment to its strategic goals.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced the quotation of additional securities on the Australian Securities Exchange (ASX), with a total of 532,182 ordinary fully paid shares being issued. This move reflects the company’s ongoing efforts to strengthen its financial position and enhance its market presence, potentially impacting its operational capabilities and investor confidence.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced an Extraordinary General Meeting scheduled for August 20, 2025, to be held both in-person in Sydney and online via Zoom. This meeting is significant for shareholders as it provides an opportunity to engage in the company’s strategic decisions and vote on key issues, reflecting Imugene’s commitment to maintaining transparent and inclusive governance practices.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced the application for quotation of 92,495 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategic efforts to strengthen its financial position and support its ongoing development projects in cancer immunotherapy, potentially impacting its market positioning and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited announced a webinar to present the latest data from its Phase 1b trial of the azer-cel drug. The webinar, hosted by key company executives, is an opportunity for shareholders and investors to gain insights into the progress of this promising therapy. This event underscores Imugene’s commitment to transparency and stakeholder engagement as it advances its innovative cancer treatment pipeline.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited is offering up to 68,236,857 new shares to placement subscribers and 45,454,545 new shares to eligible shareholders under a Share Purchase Plan, both at an issue price of $0.33 per share, aiming to raise a total of approximately $37.5 million. The offer includes attaching options and piggyback options, providing potential future investment opportunities, which may impact the company’s financial strategy and shareholder value.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has released a capital raising presentation aimed at securing funds to advance its cancer treatment innovations. The presentation outlines the company’s strategic initiatives and growth plans, emphasizing its commitment to developing cutting-edge immuno-oncology therapies. This move is expected to strengthen Imugene’s position in the biotechnology sector, potentially offering significant benefits to stakeholders by accelerating the development of its promising cancer treatments.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced a proposed issue of securities under a securities purchase plan, which includes the issuance of new quoted options and ordinary fully paid shares. This strategic move is aimed at bolstering the company’s financial position and supporting its ongoing research and development efforts in cancer immunotherapy, potentially enhancing its market position and offering value to its stakeholders.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced a proposed issue of securities, which includes the issuance of over 170 million new securities in various forms, such as quoted options and ordinary shares. This strategic move is expected to enhance the company’s financial flexibility and support its ongoing research and development efforts in the field of cancer immunotherapy, potentially strengthening its market position and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has successfully raised $22.5 million through a placement to institutional and sophisticated investors, and is launching a $15 million Share Purchase Plan (SPP) for existing shareholders. The funds will support the azer-cel program’s pivotal clinical trial and extend the company’s funding runway into mid-2027, enhancing its operational stability and market positioning.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has requested a trading halt on its securities pending an announcement regarding a proposed capital raising. This move indicates a strategic financial decision that could impact the company’s operations and market positioning, with potential implications for investors and stakeholders.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited announced promising results from its Phase 1b trial of azer-cel, an allogeneic CD19 CAR T therapy for relapsed DLBCL. The trial showed a 75% overall response rate, with 6 complete responses and 3 partial responses, highlighting azer-cel’s potential in patients who have failed multiple lines of therapy. The company plans to meet with the US FDA in late 2025 to discuss a pivotal trial, indicating significant progress in addressing high-unmet-need populations.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has received a $5.8 million R&D tax refund from the Australian Government, which will support the further development of its immuno-oncology pipeline. This financial boost is expected to enhance the company’s clinical efforts and strengthen its position in the rapidly growing global market for cancer treatments, benefiting stakeholders and potentially advancing the effectiveness of cancer therapies.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced the dosing of the first patient in Australia for its Phase II Neo-POLEM clinical trial, which investigates the PD1-Vaxx vaccine’s potential to enhance treatment outcomes for a specific type of colorectal cancer. This trial, conducted in collaboration with Cancer Research UK and other partners, aims to assess the vaccine’s efficacy in reducing tumor size and improving survival rates, offering hope for patients with this challenging cancer subtype.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene Limited stock, see the AU:IMU Stock Forecast page.
Imugene Limited announced that all resolutions were passed at their Extraordinary General Meeting, as decided by a poll. This outcome supports the company’s strategic direction and reinforces its commitment to advancing its pipeline of immuno-oncology therapies, potentially strengthening its position in the global cancer treatment market.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene Limited stock, see the AU:IMU Stock Forecast page.
Imugene Limited announced its progress in developing cancer therapies, with a 57% complete response rate in blood cancer treatments and plans to initiate a pivotal Phase 2/3 trial in 2026. The company is also advancing its novel virus therapies for solid cancers, showing promising results in bile tract cancer, and is actively pursuing partnerships and cost control measures to enhance its market position.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene Limited stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced the allowance of a core US patent for its onCARlytics platform, a significant step in securing its intellectual property in the major oncology market of the United States. This patent, which protects the method of composition and use of its CF33-CD19 oncolytic virotherapy in combination with CD19 targeting CAR T cell therapies, is valid until 2038. The patent strengthens Imugene’s position in the global healthcare market, following a similar patent allowance in China. The company’s ongoing OASIS trial in the US aims to further explore the potential of this technology in treating solid tumors.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene Limited stock, see the AU:IMU Stock Forecast page.
Imugene Limited announced the cessation of certain securities, including 14,796,793 restricted stock units and 6,666,666 options, due to unmet conditions. This development may impact the company’s capital structure and could influence stakeholder perceptions regarding the company’s operational strategies and future growth prospects.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene Limited stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced the activation of the first site in Australia for its Phase II Neo-POLEM clinical trial, which investigates the PD1-Vaxx vaccine’s potential to improve treatment outcomes for patients with a specific subtype of colorectal cancer. This trial, conducted in collaboration with Cancer Research UK and other partners, aims to determine the vaccine’s effectiveness in reducing tumor size and improving survival rates, potentially offering a significant advancement in immunotherapy for colorectal cancer patients.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene Limited stock, see the AU:IMU Stock Forecast page.
Imugene Limited has appointed Dr. John Byon as its new Chief Medical Officer. Dr. Byon, who has a strong background in oncology drug development, has been pivotal in advancing Imugene’s strategy to combine its allogeneic CAR-T therapy, azer-cel, with interleukin-2 (IL-2), significantly improving treatment outcomes for patients with relapsed/refractory diffuse large B-cell lymphoma. His appointment is expected to further strengthen Imugene’s clinical pipeline and its efforts towards commercializing innovative cancer treatments.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene Limited stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced a security consolidation, impacting various options and warrants with expiration dates ranging from 2026 to 2030. This reorganization, effective from July 2025, aims to streamline the company’s capital structure, potentially enhancing its market positioning and operational efficiency.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene Limited stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced a 34:1 share consolidation to improve market perception and attract institutional investors, aligning with a crucial phase in its Azer-Cel program. Additionally, the company seeks shareholder approval to issue up to 1.2 billion new shares pre-consolidation, providing flexibility for potential funding opportunities, ensuring sustained growth and operational support through 2025.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene Limited stock, see the AU:IMU Stock Forecast page.
Imugene Limited has issued an addendum to its Notice of Extraordinary General Meeting, detailing amendments to the original notice and explanatory memorandum. The meeting is scheduled for June 26, 2025, and will be held both in-person and online. The addendum includes corrections to the exercise prices for a security code and provides guidance for shareholders on voting queries. This announcement ensures clarity and accuracy for shareholders ahead of the meeting, reflecting Imugene’s commitment to transparency and effective communication with its stakeholders.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene Limited stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced an Extraordinary General Meeting (EGM) scheduled for June 26, 2025, to be held both in-person in Sydney and online via Zoom. This meeting will allow shareholders to participate in company decisions, reflecting Imugene’s commitment to engaging stakeholders and ensuring their involvement in the company’s strategic direction.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene Limited stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced the issuance of unquoted equity securities, including 95,653,854 restricted stock units and 3,570,072 performance rights awards, as part of an employee incentive scheme. This move is likely aimed at aligning employee interests with company goals and could impact the company’s operational dynamics and market positioning by potentially enhancing employee motivation and retention.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene Limited stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced the cessation of several securities, including options that have expired or lapsed due to unmet conditions. This announcement reflects a routine adjustment in the company’s capital structure, which may influence investor perceptions and the company’s financial strategy moving forward.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene Limited stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced a proposed consolidation of its share capital, which will be voted on at an upcoming Extraordinary General Meeting. The consolidation will reduce the number of shares on issue from approximately 7.47 billion to about 219.6 million, without materially affecting the aggregate value of each shareholding or the company’s market capitalization. This move is expected to increase the market price per share, reflecting the reduced number of shares, and will also apply to all options currently on issue.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene Limited stock, see the AU:IMU Stock Forecast page.